IL18 and Miyoshi myopathy: The research results show that miR-22 inhibited the activating NLRP3 inflammasome by targeting, reduced the activity of A375 cells in mouse cutaneous MM tumors, and regulated the expression of inflammatory factors, including IL-1β and IL-18, which strengthened the protection effects of mouse subcutaneous tissues.